Compare EZPW & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EZPW | COLL |
|---|---|---|
| Founded | 1989 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 1996 | 2015 |
| Metric | EZPW | COLL |
|---|---|---|
| Price | $25.43 | $45.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $24.00 | ★ $51.17 |
| AVG Volume (30 Days) | ★ 1.1M | 287.6K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.09 | N/A |
| EPS | 0.55 | ★ 1.28 |
| Revenue | ★ $747,954,000.00 | $631,449,000.00 |
| Revenue This Year | $23.29 | $26.20 |
| Revenue Next Year | $10.88 | $3.54 |
| P/E Ratio | $45.64 | ★ $34.95 |
| Revenue Growth | ★ 2.39 | N/A |
| 52 Week Low | $12.89 | $23.23 |
| 52 Week High | $26.35 | $50.79 |
| Indicator | EZPW | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 66.78 | 44.64 |
| Support Level | $20.65 | $43.81 |
| Resistance Level | $26.35 | $48.74 |
| Average True Range (ATR) | 0.92 | 1.30 |
| MACD | 0.04 | -0.13 |
| Stochastic Oscillator | 72.09 | 21.80 |
EZCORP Inc is a United States-based company engaged in offering pawn loans in the United States and Mexico. It also offers short-term unsecured loans and other consumer financial products, and buys and sells second-hand goods. The operating segments of the company are U.S. Pawn, Latin America Pawn, and Other Investments. The U.S. Pawn segment includes all pawn activities in the United States. The Latin America Pawn segment includes all pawn activities in Mexico and other parts of Latin America. The company generates revenue from merchandise sales, jewelry scrapping sales, and pawn service charges, of which key revenue is derived from the merchandise sales, which are mainly collateral forfeited from pawn lending operations and used merchandise purchased from the customers.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.